MedTrace Logo

HMGB1 Release From Hemorrhagic Shock Patients

NCT03535441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2018-05-24

No results posted yet for this study

Summary

It is reported that high mobility group box 1 (HMGB1), a non-histone nuclear protein, can serve as an alarmin with damage associated molecular patterns to activate immune responses in the early stages of hemorrhagic shock (HS). However, the origin of HMGB1 and how it is released following HS is poorly understood. In this study, we teased out this mechanism. We try to record the concentration of serum HMGB1 protein following HS in clinical patients.

Conditions

  • Intensive Care Unit
  • Hemorrhagic Shock
  • Adult Disease

Sponsors & Collaborators

  • Xingui Dai

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2018-04-11
Completion
2018-05-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03535441 on ClinicalTrials.gov